Efficacy News and Research

RSS

FDA accepts Sangamo BioSciences' IND for SB-BCLmR-HSPC genome editing approach

Sangamo BioSciences, Inc. announced today that an Investigational New Drug (IND) application for the company's SB-BCLmR-HSPC genome editing approach, which is designed to provide a one-time lasting therapy for beta-thalassemia, has been accepted by the U.S. Food and Drug Administration and is now active.

4 Feb 2015

Parents can pass silenced genes to offspring through a specific mechanism

For more than a century, scientists have understood the basics of inheritance: if good genes help parents survive and reproduce, the parents pass those genes along to their offspring. And yet, recent research has shown that reality is much more complex: genes can be switched off, or silenced, in response to the environment or other factors, and sometimes these changes can be passed from one generation to the next.

4 Feb 2015

Spaceflight may be associated with accelerated aging of the immune system

As the world waits to see if Mars One can establish a human colony on Mars, scientists are working to determine the long-term consequences of living in low or no-gravity conditions, such as those that might exist on the trip to another planet. New research published online in The FASEB Journal, shows that spaceflight may be associated with a process of accelerated aging of the immune system.

4 Feb 2015

Study demonstrates therapeutic potential of new class of synthetic oligonucleotides for DMD treatment

Research efforts associating scientists from the CNRS, UVSQ and INSERM within the Laboratoire END-ICAP, working in collaboration with a team from the University of Bern, has demonstrated the therapeutic potential of a new class of synthetic oligonucleotides in the treatment of Duchenne muscular dystrophy (DMD) using RNA "surgery".

4 Feb 2015

Study could lead to potential therapeutic targets to treat Ewing Sarcoma

A University of Colorado Cancer Center study published in the journal PLoS One finds alterations in expression of genes PIK3R3 and PTEN, more commonly observed in adult tumors, in the rare, young-adult bone cancer Ewing Sarcoma, potentially offering ways to improve therapy.

4 Feb 2015

Researchers offer critical new information about head and neck squamous cell cancer

Head and neck squamous cell cancer (HNSCC) ranks among the top ten most prevalent cancers in the United States. Despite its prevalence, little is known about how this cancer develops and spreads. However, in a paper published in the January 29, 2015 edition of Nature, researchers offer critical new information about head and neck cancers.

4 Feb 2015

COMBACTE-MAGNET project launched to study new treatment options for infections caused by MDR-GNB

Today 33 European academic partners and 5 pharmaceutical companies are launching a new project, COMBACTE-MAGNET, under the IMI antimicrobial resistance research programme New Drugs 4 Bad Bugs (ND4BB).

4 Feb 2015

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints.

4 Feb 2015

Study: Smoking increases mortality risk among colorectal cancer survivors

Colorectal cancer survivors who smoke cigarettes were at more than twice the risk of death than non-smoking survivors, adding to existing evidence that cigarette smoking is associated with higher all-cause and colorectal cancer-specific mortality.

4 Feb 2015

Janssen granted Priority Review from FDA for YONDELIS (trabectedin) NDA to treat STS patients

Janssen Research & Development, LLC announced today that the U.S. Food and Drug Administration has granted Priority Review for the New Drug Application (NDA) for YONDELIS (trabectedin) to treat patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline.

3 Feb 2015

Large clinical trial to assess safety, efficacy of two experimental Ebola vaccines opens in Liberia

A large clinical trial to assess the safety and efficacy of two experimental vaccines to prevent Ebola virus infection is now open to volunteers in Liberia. The trial is being led by a recently formed Liberia-U.S. clinical research partnership and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

3 Feb 2015

ABIVAX doses first HIV positive patient in ABX464 Phase IIa clinical trial

ABIVAX, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that enrolment has been initiated and the first HIV positive patient dosed in a Phase IIa clinical trial of ABX464.

2 Feb 2015

TSRI researchers awarded grant to develop novel method for detecting DNA damage in stem cells

A team at The Scripps Research Institute has won a $1,784,000 grant from the California Institute for Regenerative Medicine (CIRM). The funding will support the development of a new method for detecting DNA damage in stem cells to ensure that only the highest quality cells are used in transplantation or therapy.

31 Jan 2015

Project Spark to advance neuroprotective drug for schizophrenia-associated cognitive impairment

A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.

31 Jan 2015

Nanoscale DNA tool to detect molecular behavior

A complex interplay of molecular components governs almost all aspects of biological sciences - healthy organism development, disease progression, and drug efficacy are all dependent on the way life's molecules interact in the body. Understanding these bio-molecular interactions is critical for the discovery of new, more effective therapeutics and diagnostics to treat cancer and other diseases, but currently requires scientists to have access to expensive and elaborate laboratory equipment.

31 Jan 2015

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

AbbVie released top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan.

31 Jan 2015

Shire announces FDA approval of Vyvanse Capsules for binge eating disorder

Shire plc announced today that the U.S. Food and Drug Administration approved Vyvanse (lisdexamfetamine dimesylate) Capsules (CII), the first and only medication for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults, shown to significantly reduce the mean number of binge days per week.

30 Jan 2015

Centura Health, DaVita HealthCare Partners jointly unveil FullWell

Centura Health and DaVita HealthCare Partners today unveiled FullWell, the brand name of the two partners' recently announced joint venture, a company that aims to bring greater value to health care and lower costs for consumers in Colorado and Kansas.

30 Jan 2015

Nuvo Research announces topline results from WF10 Phase 2 allergic rhinitis clinical trial

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced the results of its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial conducted in Germany to compare the safety and efficacy of WF10 and its main constituents (sodium chlorite and sodium chlorate) with saline in patients with refractory allergic rhinitis and to compare the safety and efficacy of WF10 and its main constituents.

30 Jan 2015

AstraZeneca announces research collaborations to use genome-editing tool for drug discovery and development

AstraZeneca today announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company’s key therapeutic areas.

30 Jan 2015

Efficacy News and Research

FDA accepts Sangamo BioSciences' IND for SB-BCLmR-HSPC genome editing approach

Parents can pass silenced genes to offspring through a specific mechanism

Spaceflight may be associated with accelerated aging of the immune system

Study demonstrates therapeutic potential of new class of synthetic oligonucleotides for DMD treatment

Study could lead to potential therapeutic targets to treat Ewing Sarcoma

Researchers offer critical new information about head and neck squamous cell cancer

COMBACTE-MAGNET project launched to study new treatment options for infections caused by MDR-GNB

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Study: Smoking increases mortality risk among colorectal cancer survivors

Janssen granted Priority Review from FDA for YONDELIS (trabectedin) NDA to treat STS patients

Large clinical trial to assess safety, efficacy of two experimental Ebola vaccines opens in Liberia

ABIVAX doses first HIV positive patient in ABX464 Phase IIa clinical trial

TSRI researchers awarded grant to develop novel method for detecting DNA damage in stem cells

Project Spark to advance neuroprotective drug for schizophrenia-associated cognitive impairment

Nanoscale DNA tool to detect molecular behavior

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

Shire announces FDA approval of Vyvanse Capsules for binge eating disorder

Centura Health, DaVita HealthCare Partners jointly unveil FullWell

Nuvo Research announces topline results from WF10 Phase 2 allergic rhinitis clinical trial

AstraZeneca announces research collaborations to use genome-editing tool for drug discovery and development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News